Hussein Mahmoud R, Al-Sabae Tarek M, Georgis Marcelle N
Pathology Departments, School of Medicine and South Egypt Cancer Institute, Assuit University, Assuit, Egypt.
Cancer Biol Ther. 2005 Mar;4(3):324-8. doi: 10.4161/cbt.4.3.1568. Epub 2005 Mar 28.
Lymphomagenesis involves poorly understood alterations in the proapoptotic and prosurvival molecules. In the Upper Egypt, the clinicopathologic and genetic characteristics (p53 and Bcl-2) of the lymphoproliferative lesions (reactive hyperplasia, RH; Non-Hodgkin's lymphoma, NHL and Hodgkin's disease, HD) is unknown.
To examine the lymphoproliferative lesions for: (1) their clinicopathologic features, (2) the p53, and Bcl-2 protein expression and (3) the correlation between the clinicopathologic features and the genetic alterations.
p53 and Bcl-2 protein expression was immunohistochemically evaluated in 68 lesions including 47 NHL, 10 HD, and 11 RH. The average weighted scores reflecting staining intensity and the percentage of positive cells were calculated.
Clinically: 1) the mean age incidence gradually increased from HD to RH to NHL (16.1 +/- 5.9, 36.6 +/- 7.45 and 46.74 +/- 3.2, p = 0.001) and 2) NHL and RH showed slight female (1.1:1) and male (1.2:1) sex predilection, respectively. Also, HD has male (2.3:1) sex predilection. The bcl-2 average weighted scores showed gradual downregulation with the transition from low to intermediate to high grade NHL (9.50 +/- 1.12 > 6.67 +/- 0.70 > 6.28 +/- 0.83, p = 0.041). Alternatively, the p53 average weighted scores showed gradual upregulation with the transition from low to intermediate to high grade NHL (0.40 +/- 0.22 < 1.72 +/- 0.35 < 2.15 +/- 0.52, p = 0.023). There was a negative correlation between bcl-2 and p53 protein expression in NHL (r = -0.221, p = 0.165). In HD, Reed-Sternberg cells and their variants showed positive and negative reactivity for Bcl-2 and p53 protein expression, respectively.
In the Upper Egypt: (1) lymphoproliferative lesions had some peculiar clinicopathologic features and (2) Bcl-2 and p53 proteins are altered in the lymphoproliferative lesions.
淋巴瘤的发生涉及促凋亡和抗凋亡分子中尚不清楚的改变。在上埃及地区,淋巴增生性病变(反应性增生、非霍奇金淋巴瘤和霍奇金病)的临床病理和遗传特征(p53和Bcl-2)尚不清楚。
研究淋巴增生性病变的:(1)临床病理特征;(2)p53和Bcl-2蛋白表达;(3)临床病理特征与基因改变之间的相关性。
采用免疫组织化学方法评估68例病变组织中p53和Bcl-2蛋白的表达,其中包括47例非霍奇金淋巴瘤、10例霍奇金病和11例反应性增生。计算反映染色强度和阳性细胞百分比的平均加权分数。
临床上:1)平均发病年龄从霍奇金病到反应性增生再到非霍奇金淋巴瘤逐渐升高(16.1±5.9、36.6±7.45和46.74±3.2,p = 0.001);2)非霍奇金淋巴瘤和反应性增生分别显示轻微的女性(1.1:1)和男性(1.2:1)偏好。此外,霍奇金病有男性(2.3:1)偏好。Bcl-2平均加权分数显示随着非霍奇金淋巴瘤从低级别到中级再到高级别的转变逐渐下调(9.50±1.12 > 6.67±0.70 > 6.28±0.83,p = 0.041)。相反,p53平均加权分数显示随着非霍奇金淋巴瘤从低级别到中级再到高级别的转变逐渐上调(0.40±0.22 < 1.72±0.35 < 2.15±0.52,p = 0.023)。非霍奇金淋巴瘤中Bcl-2和p53蛋白表达之间存在负相关(r = -0.221,p = 0.165)。在霍奇金病中,里德-斯腾伯格细胞及其变异体对Bcl-2和p53蛋白表达分别显示阳性和阴性反应。
在上埃及地区:(1)淋巴增生性病变具有一些独特的临床病理特征;(2)淋巴增生性病变中Bcl-2和p53蛋白发生改变。